Roche. File photo

Roche faces an­oth­er de­lay in strug­gle to nav­i­gate Spark deal past reg­u­la­tors — but this one is very short

Roche to­day is­sued the lat­est in a long string of de­lays of its $4.3 bil­lion buy­out of Philadel­phia-based Spark Ther­a­peu­tics. The de­lay comes as lit­tle sur­prise — it is their 10th in as many months — as their most re­cent de­lay was sched­uled to ex­pire be­fore a key reg­u­la­to­ry dead­line.

But it is no­table for its length: 6 days.

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.